Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
journalStr:"BMC medicine"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?lookfor=%22Shi%2C+Yuankai%22&type=Person&filter%5B%5D=journalStr%3A%22BMC+medicine%22
/vufind/Search/Results?lookfor=%22Shi%2C+Yuankai%22&type=Person&filter%5B%5D=journalStr%3A%22BMC+medicine%22
Search /vufind/Search2/Results?lookfor=%22Shi%2C+Yuankai%22&type=Person&filter%5B%5D=journalStr%3A%22BMC+medicine%22
PubPharm (11)
1
Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer : a pooled analysis from two phase 2 studies
enthalten in:
BMC medicine
| 2023
von
Hu, X.
|
Zhang, S.
|
Ma, Z.
| +27
Wird geladen...
2
Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies
enthalten in:
BMC medicine
| 2023
von
Hu, X.
|
Zhang, S.
|
Ma, Z.
| +27
Wird geladen...
3
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients : a single-arm, multicenter phase II study (INTELLECT)
enthalten in:
BMC medicine
| 2023
von
Shi, Y.
|
Chen, J.
|
Zhang, H.
| +30
Wird geladen...
4
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)
enthalten in:
BMC medicine
| 2023
von
Shi, Y.
|
Chen, J.
|
Zhang, H.
| +30
Wird geladen...
5
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)
enthalten in:
BMC medicine
| 2023
von
Shi, Y.
|
Chen, J.
|
Zhang, H.
| +30
Wird geladen...
6
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study
enthalten in:
BMC medicine
| 2023
von
Shi, Y.
|
Zhou, J.
|
Zhao, Y.
| +13
Wird geladen...
7
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study
enthalten in:
BMC medicine
| 2023
von
Shi, Y.
|
Zhou, J.
|
Zhao, Y.
| +13
Wird geladen...
8
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study
enthalten in:
BMC medicine
| 2023
von
Shi, Y.
|
Zhou, J.
|
Zhao, Y.
| +13
Wird geladen...
9
Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer : a multicenter, open-label, first-in-human phase 1 study
enthalten in:
BMC medicine
| 2022
von
Xing, P.
|
Zhao, Q.
|
Zhang, L.
| +5
Wird geladen...
10
Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study
enthalten in:
BMC medicine
| 2022
von
Xing, P.
|
Zhao, Q.
|
Zhang, L.
| +5
Wird geladen...
1
2
Nächster »
[2]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Zeitschrift: BMC medicine
Medienart
11
Aufsätze
11
E-Artikel
11
E-Ressourcen
Zeitschriftentitel
BMC medicine
Thema
6
Anaplastic lymphoma kinase
6
Non-small cell lung cancer
6
Tyrosine kinase inhibitor
5
NSCLC
4
EC 2.7.10.1
4
Journal Article
4
Protein Kinase Inhibitors
4
Research Support, Non-U.S. Gov't
3
BPI-7711
3
CT-707
3
Conteltinib
3
Iruplinalkib
3
Phase 1 study
3
Rezivertinib
3
Third-generation EGFR TKI
3
WX-0593
2
53AH36668S
2
AST2818
2
Anaplastic Lymphoma Kinase
2
CNS
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
8
2023
3
2022
Erscheinungsjahr(e)
Von:
Bis:
Sprache
11
Englisch
Haven't found what you're looking for?
Wird geladen...